Axonis Therapeutics Secures Major Funding to Advance Neurological Therapies
Axonis Therapeutics, a pioneering biotechnology company, has successfully completed an impressive $115 million Series A financing round. This oversubscribed financing showcases the strong support from leading investors in the life sciences sector. With this significant capital injection, Axonis is poised to accelerate the clinical development of innovative therapies targeting neurological disorders.
Funding to Propel Clinical Development
The proceeds from this funding will primarily focus on advancing Axonis' lead candidate, AXN-027, through clinical proof-of-concept stages. AXN-027 is a first-in-class oral small molecule designed to enhance the function of KCC2, a vital chloride transporter in the central nervous system. This innovative treatment aims to address critical issues related to epilepsy and pain management.
Next Generation Developments in Focus
In addition to fostering the development of AXN-027, the financing will also help fund further research into next-generation compounds that target KCC2 for treating various neurological conditions, including psychiatric and neurodevelopmental disorders.
Support from Renowned Life Sciences Investors
The financing was co-led by Cormorant Asset Management and venBio Partners, with additional investments from prominent entities such as Sofinnova Investments, MRL Ventures Fund, Perceptive Advisors, and others. This strong backing from seasoned investors signals a robust confidence in Axonis’ mission.
Strengthening Leadership and Governance
In conjunction with securing this financing, Axonis has announced new appointments to its Board of Directors. Notable additions include Dr. Raymond J. Kelleher, Managing Director at Cormorant Asset Management, and Dr. Jonathan Leff, Executive Partner at Sofinnova Investments. The integration of these experts brings valuable experience and insight, further enhancing Axonis’ strategic leadership.
A Vision for Future Therapies
Joanna Stanicka, Ph.D., Axonis’ Chief Executive Officer, expressed her enthusiasm: "Our vision involves advancing a portfolio of oral KCC2 therapeutics aimed at restoring functional inhibition in the CNS, addressing neurological disorders without debilitating side effects. This financing represents a pivotal milestone for our team as we prepare to push our science into the clinic this year."
Corey Goodman, Ph.D., Executive Chair and co-founder, echoed these sentiments, noting the remarkable progress made at Axonis and the potential impact of their research on the future of patient care.
Addressing Unmet Needs in Neurology
Current therapies for epilepsy and pain often fall short for a significant number of patients. Many do not tolerate or respond adequately to first-line medications, primarily due to impaired synaptic inhibition. Axonis' approach of utilizing oral KCC2 potentiators is designed to restore this inhibition, providing new hope for those resistant to standard treatments.
Collaborative Efforts and Commitment
Raymond J. Kelleher highlighted the potential of Axonis’ novel approach in reshaping treatment protocols for patients. The ambition is to create impactful medicines that address gaps in current therapeutic offerings, especially for conditions like epilepsy and chronic pain.
Meet the Leadership Team
Joanna Stanicka leads a talented team dedicated to developing cutting-edge neuro-focused treatments. As a Harvard-trained scientist and award-winning entrepreneur, she brings invaluable expertise to Axonis. Alongside her, Shane Hegarty, Ph.D., serves as Chief Scientific Officer, contributing extensive experience in neuroscience research.
Moreover, the company recently appointed Dr. Donald Manning as Chief Medical Officer and Jeff Imbaro as Chief Operating Officer, bolstering the team with profound clinical and business expertise.
About Axonis Therapeutics
Axonis Therapeutics is on a mission to revolutionize the treatment of neurological disorders through innovative research and development. By focusing primarily on KCC2, which plays a critical role in mediating inhibitory neurotransmission, Axonis aims to deliver first- and best-in-class medicines. The company's foundational research has its roots in groundbreaking discoveries from esteemed institutions. Their proprietary discovery engine stems from years of expertise aimed at leading this promising drug market.
Axonis values the invaluable support from various institutional partners and organizations, grateful for the grants awarded that aid their mission to serve patients effectively. They are dedicated to improving the quality of life for individuals facing neurological challenges.
Frequently Asked Questions
1. What is the purpose of the $115 million financing for Axonis Therapeutics?
The financing is aimed at advancing clinical development of AXN-027 and supporting research into next-generation compounds targeting KCC2 for treating neurological disorders.
2. What is AXN-027 designed to do?
AXN-027 is an oral small molecule that enhances the function of KCC2, crucial for inhibiting neurotransmission, which can help in treating epilepsy and pain.
3. Who are the investors involved in this financing round?
The financing round was co-led by Cormorant Asset Management and venBio Partners, with participation from several other notable life sciences investors.
4. What is the significance of KCC2 in treating neurological disorders?
KCC2 is a major chloride transporter involved in inhibitory neurotransmission; targeting it can help restore synaptic inhibition and address drug resistance issues.
5. Who is leading Axonis Therapeutics?
Axonis is led by Joanna Stanicka, Ph.D., who is supported by a skilled team and recently strengthened with new appointments in key positions.
